Das Hepatozelluläre Karzinom - Screening, Diagnostik und Therapie

Translated title of the contribution: Hepatocellular carcinoma - Screening, diagnostic and therapy

Edouard Matevossian, Volker Aßfalg, Dietrich Doll, Gregor Babaryka, Moritz Wildgruber, Martin Dobritz, Stefan Thorban, Helmut Friess, Arno Konberg

Research output: Contribution to journalArticlepeer-review


Hepatocellular carcinoma (HCC) is the fifth most common cancer, it is a terminal complication of chronic inflammatory and fibrotic liver disease, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infection. Patients with cirrhosis are at the highest risk and should be monitored every 6 months. Major factors contributing to the increased incidence of HCC include an increase in the incidence of type C chronic hepatitis and an increase in the incidence of cirrhosis of the liver, which in turn are the result of blood transfusions received about 30 years ago. Surveillance can lead to diagnosis at early stages, when the tumour might be curable by resection, liver transplantation, or percutaneous treatment. Most HCC patients are diagnosed at advanced stages and receive palliative treatment. Only chemoembolisation improves survival in well-selected patients with unresectable HCC. This article focuses on the screening, diagnosis, and management of HCC and new clinical and scientific developments.

Translated title of the contributionHepatocellular carcinoma - Screening, diagnostic and therapy
Original languageGerman
Pages (from-to)282-284
Number of pages3
Issue number6-7
StatePublished - 2012
Externally publishedYes


Dive into the research topics of 'Hepatocellular carcinoma - Screening, diagnostic and therapy'. Together they form a unique fingerprint.

Cite this